

Dr Goutam Chandra Joined the Center for Development and Aging Research (CDAR) in Inter-University Center for Biomedical Research (IUCBR) as a Senior Scientist in Geriatric Diseases on April 2017. Dr. Chandra is a pharmaceutical scientist having extensive research experience on molecular basis of drug action. He holds a Masters' degree on Pharmaceutics from Jadavpur University and a PhD on Neuropharmacology from Indian Institute of Chemical Biology, Kolkata. He previously served as a faculty member in the Department of Pharmaceutics in Himalayan Pharmacy Institute, North Bengal University, Sikkim.

Dr Chandra received advanced training on electrophysiology from University of Hong Kong. He did postdoctoral research from National Institutes of Health, Bethesda; Rush University Medical Center, Chicago and Children's National Medical Center, Washington DC, where he worked on elucidating novel cellular and molecular signaling pathways that lead to specific cellular death in a number of neurodegenerative and neuromuscular diseases. His research led to the discovery of a few novel molecules having therapeutic potential for treating neurodegenerative diseases like Infantile Batten disease and Parkinson's disease (PD). At present, he has one US patent and 16 peer-reviewed research publications with a cumulative IF of 100 and h-indices of 11.

At IUCBR, Dr Chandra is currently establishing his research lab on Aging and Geriatric Diseases. His current research interest include development of innovative therapeutic strategies for ageing-associated neurodegenerative disorders like PD. Using multi-dimensional approaches, his research team is trying to understand how defects in cellular protein synthesis, transport and/or degradation result in death of specific population of neurons in PD and other neurodegenerative disorders.

Selected recent publications:

- Bagh MB, Peng S, **Chandra G**, Zhang Z, Singh SP, Pattabiraman N, Liu A and Mukherjee A. Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in a neurodegenerative lysosomal storage disease model. *Nat Commun.* 8, 2017, 14612.
- **Chandra G**, Rangasamy SB, Roy A, Kordower JH, and Pahan K. Neutralization of Rantes and Eotaxin prevents the loss of dopaminergic neurons in a mouse model of Parkinson's Disease. *J Biol Chem.* 291, 2016, 15267-81.
- **Chandra G**, Bagh MB, Peng S, Saha A, Sarkar C, Moralle M, Zhang Z and Mukherjee AB. Cln1 gene disruption in mice reveals a common pathogenic link between two of the most lethal childhood neurodegenerative lysosomal storage disorders. *Hum Mol Genet.* 24, 2015, 5416-32.
- Levin SW, Baker EH, Zein WM, Zhang Z, Quezado ZMN, Miao N, Gropman A, Griffin KJ, Bianconi S, **Chandra G**, Khan OI, Caruso RC, Liu A, Mukherjee AB. A Bench-to-Bedside clinical trial using a combination of Cystagon and Mucomyst for patients with INCL. *Lancet Neurol.* 13, 2014, 777-87.
- Sarkar C*, **Chandra G***, Peng S, Zhang Z, Liu A, Mukherjee AB. Neuroprotection and lifespan extension in Ppt1(-/-) mice by NtBuHA: therapeutic implications for INCL. *Nat Neurosci.* 16, 2013, 1608-17. (* **equally contributed**)